Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Idera completes follow-on

Idera Pharmaceuticals Inc. (NASDAQ:IDRA), Cambridge, Mass.
Business: Cancer, Infectious, Autoimmune
Date completed: 5/7/13
Type:

Read the full 141 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE